Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma.

PubWeight™: 1.18‹?› | Rank: Top 10%

🔗 View Article (PMID 15671541)

Published in Clin Cancer Res on January 01, 2005

Authors

Pardeep Bhatia1, M Melinda Sanders, Marc F Hansen

Author Affiliations

1: Center for Molecular Medicine, University of Connecticut Health Center, Farmington, Connecticut 06030, USA.

Articles citing this

Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer. PLoS One (2013) 1.64

Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One (2011) 1.44

Spontaneous apoptosis of blood dendritic cells in patients with breast cancer. Breast Cancer Res (2005) 1.14

RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS One (2013) 1.08

Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling. PLoS One (2010) 1.03

Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling. Mol Cancer Ther (2011) 0.97

The Possible Interaction between Receptor Activator of Nuclear Factor Kappa-B Ligand Expressed by Extramammary Paget Cells and its Ligand on Dermal Macrophages. J Invest Dermatol (2015) 0.95

RANKL/RANK/OPG: key therapeutic target in bone oncology. Curr Drug Discov Technol (2008) 0.87

Osteoprotegerin in bone metastases: mathematical solution to the puzzle. PLoS Comput Biol (2012) 0.86

Genetic polymorphism of the OPG gene associated with breast cancer. BMC Cancer (2013) 0.86

Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines. Cancer Cell Int (2012) 0.84

RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis. Geburtshilfe Frauenheilkd (2012) 0.83

Emerging candidates in breast cancer stem cell maintenance, therapy resistance and relapse. J Carcinog (2011) 0.82

Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathway. Mol Cancer Res (2010) 0.82

Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug. Br J Pharmacol (2012) 0.81

MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone. Oncotarget (2015) 0.80

Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis. BMC Cancer (2015) 0.80

Expression pattern of the apoptosis-stimulating protein of p53 family in p53+ human breast cancer cell lines. Cancer Cell Int (2013) 0.78

Emerging lung cancer therapeutic targets based on the pathogenesis of bone metastases. Int J Cell Biol (2014) 0.78

Evaluation of rs3102735 and rs2073617 Osteoprotegerin Gene Polymorphisms and the Risk of Childhood Acute lymphoblastic Leukemia in Zahedan Southeast Iran. Int J Hematol Oncol Stem Cell Res (2014) 0.78

Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences. J Bone Oncol (2012) 0.76

Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort. BMC Med (2017) 0.75

Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer. BMC Cancer (2017) 0.75

RANK-RANKL signalling in cancer. Biosci Rep (2016) 0.75

RANK overexpression as a novel esophageal cancer marker: validated immunohistochemical analysis of two different ethnicities. Int J Clin Exp Pathol (2015) 0.75

Plant-derived anticancer agents: a promising treatment for bone metastasis. Bonekey Rep (2014) 0.75